Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Catalent Inc (NY: CTLT )

58.73 +0.13 (+0.22%)
Official Closing Price Updated: 7:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Catalent Inc

< Previous 1 2
...
9 10 11 12 13 14 15 16 Next >
Catalent, Inc. Announces Fourth Quarter Fiscal Year 2022 Earnings Conference Webcast
From Catalent, Inc.
Via Business Wire
Is Novavax Stock A Buy After Omicron Results Impress Two FDA Experts?
The FDA is reviewing additional manufacturing data before making a decision. 
Via Investor's Business Daily
Catalent Announces New Operating Structure
From Catalent, Inc
Via Business Wire
Catalent, Inc. to Present at June Investor Conferences
From Catalent, Inc.
Via Business Wire
Catalent Shares Jump As Investors Cheer Revised, Better Than Expected FY22 Outlook
Via Benzinga
Recap: Catalent Q3 Earnings
Catalent (NYSE:CTLT) reported its Q3 earnings results on Tuesday, May 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Why Erytech Pharma Are Shares Moving Higher Today
Via Benzinga
Quant Ratings Updated on 75 Stocks
I decided to revise my Portfolio Grader recommendations for 75 big blue chips -- of those 75, 24 stocks were updated to a buy. 
Via InvestorPlace
Morgan Stanley Maintains Overweight Rating for Catalent: Here's What You Need To Know
Morgan Stanley has decided to maintain its Overweight rating of Catalent (NYSE:CTLT) and lower its price target from $145.00 to $132.00. Shares of Catalent are trading up 1.11% over the last 24 hours,... 
Via Benzinga
80 Biggest Movers From Yesterday
Gainers Blue Water Vaccines, Inc. (NASDAQ: BWV) shares jumped 93.1% to close at $6.45 on Tuesday on above-average volume. XORTX Therapeutics Inc. (NASDAQ: XRTX) gained 59.1% to... 
Via Benzinga
Stocks Stage Midday Rally as Bond Yields Cool
Stocks are rallying this afternoon, as investors prepare for the Federal Reserve's interest rate decision, which is due out tomorrow. 
Via Talk Markets
41 Stocks Moving In Tuesday's Mid-Day Session
Gainers SoundHound AI, Inc. (NASDAQ: SOUN) shares jumped 47.4% to $16.13. The company recently completed a SPAC merger deal last week and began trading on Thursday. Sonoma... 
Via Benzinga
Catalent, Inc. Reports Third Quarter Fiscal 2022 Results
From Catalent, Inc.
Via Business Wire
Catalent's Q2 Earnings Beat Street View, Lifts FY22 Guidance
Catalent Inc (NYSE: CTLT) has reported Q2 FY22 sales of $1. 
Via Benzinga
Expert Ratings For Catalent
Analysts have provided the following ratings for Catalent (NYSE:CTLT) within the last quarter: 
Via Benzinga
How To Attend Catalent Q3 2022 Earnings Conference Call
Catalent (NYSE:CTLT) will host a conference call at 08:15 AM ET on May 3, 2022, to discuss Q3 2022 earnings results. How to Attend Catalent (CTLT) Conference Call Follow this link to access the live... 
Via Benzinga
Catalent, Inc. Announces Third Quarter Fiscal Year 2022 Earnings Conference Webcast
From Catalent, Inc.
Via Business Wire
24 Biggest Movers From Yesterday
Gainers Vertical Aerospace Ltd. (NYSE: EVTL) Shares hiked 30.93% to close at $9.82 on Tuesday after Deutsche Bank initiated coverage of the stock. Peabody Energy Corporation (... 
Via Benzinga
Markets Fall As Investors Weigh March CPI Report
U.S. indices sold off to close Tuesday’s session following earlier strength. Investors reacted to the March CPI report and continue to assess Fed rate hike concerns. While... 
Via Benzinga
The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Pfizer Strikes COVID-19 Pill Supply Deal, Argenx Reports Positive Late-Stage Readout
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Catalent, Inc. to Present at the KeyBanc Life Sciences & MedTech Investor Forum
From Catalent, Inc.
Via Business Wire
Novo Nordisk Doubles 2025 Sales Target On Strong Wegovy Demand
Novo Nordisk A/S (NYSE: NVO) has more than doubled its target for sales of obesity drugs by 2025 after overwhelming demand for its new Wegovy drug. Novo Nordisk aims to... 
Via Benzinga
Executives Sell More Than $210M Of 5 Stocks
Spanish stocks traded higher this morning, with the IBEX 35 Index surging to the strongest level in over two weeks. Investors, meanwhile, focused on some notable insider trades.... 
Via Benzinga
The Daily Biotech Pulse: ImmunityBio Reports Positive Readout, Valneva Starts Late-Stage Chikungunya Vaccine Study, Sio Gene Shelves Parkinson's Program
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Catalent, Inc. Reports Second Quarter Fiscal 2022 Results
From Catalent, Inc.
Via Business Wire
A Bearish Sign Appears On Catalent's Chart
If history is any guide, there may be trouble ahead for shares of Catalent (NYSE:CTLT). A so-called "death cross" has formed on its chart and, not surprisingly, this could be... 
Via Benzinga
The Week Ahead In Biotech (Jan 31-Feb 5): Merck, Bristol-Myers Squibb, Lilly & Novartis Headline Large-Cap Biopharma Earnings News
The broader market weakness pervaded into the biotech sector in the week ending Jan. 28, sending stocks lower. 
Via Benzinga
Catalent, Inc. Announces Second Quarter Fiscal Year 2022 Earnings Conference Webcast
From Catalent, Inc.
Via Business Wire
This Tattooed, Cowboy-Boot-Wearing Top CEO Refuses To Go Clean Cut
John Chiminski knows he doesn't fit the traditional image of a corporate bigwig. And the Catalent CEO is not about to change. 
Via Investor's Business Daily
FDA Concerns At Catalent Site Spurred Novo Nordisk's Wegovy Supply Woes: Report
Last week, Catalent Inc (NYSE: CTLT) received an FDA write-up for its syringe filling facility in Belgium, "allegedly" the culprit behind supply shortage for... 
Via Benzinga
< Previous 1 2
...
9 10 11 12 13 14 15 16 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.